Key result
Topical timolol withdrawal resolves bradyarrhythmias in ~73% of cases, though some require permanent pacemakers.
Why the study?
Systemic absorption of topical timolol may cause clinically significant bradyarrhythmias that can be overlooked during cardiovascular assessment, prompting a systematic review to characterize the clinical features, exposure patterns, management, and outcomes of reported cases.
Systematic Review (n=33)
Topical ophthalmic timolol can cause clinically significant sinus bradycardia and high-grade AV block via systemic absorption, warranting careful medication review in patients presenting with unexplained bradyarrhythmias.
Answers are grounded in this paper and cite their sources.
Clinicians should consider topical timolol in unexplained bradyarrhythmias; case reports leave open whether prospective monitoring changes outcomes.
Timolol is widely prescribed for glaucoma and ocular hypertension. Despite topical administration, systemic absorption may cause clinically significant bradyarrhythmias, which can be overlooked during cardiovascular assessment. This systematic review aimed to characterize the clinical features, exposure patterns, management, and outcomes of reported cases. PubMed/MEDLINE, Embase, Scopus, and Google Scholar were searched from inception through December 2025 for case reports and case series describing bradyarrhythmias temporally associated with topical timolol exposure. Patient-level data were independently extracted by two reviewers and synthesized descriptively without meta-analysis. Twenty-six publications involving 33 patients were included. The median age among 31 adults was 69 years (IQR, 61.5–74.5), and 19 patients (57.6%) were older than 65 years. Exposure was predominantly ophthalmic (30 patients; 90.9%). Treatment duration of at least one month was documented in 14 of 32 non-fetal patients (43.8%), whereas numerical dose-to-bradyarrhythmia latency was reported in only four cases (12.1%). Sinus bradycardia was explicitly documented in 20 patients (60.6%) and atrioventricular block in eight (24.2%), including five (15.2%) with complete block. Timolol was discontinued, withheld, or advised to be discontinued in 30 of 32 non-fetal patients (93.8%). Favorable clinical or rhythm outcomes following withdrawal were reported in 24 patients (72.7%), although concurrent interventions limited causal attribution. Permanent pacemaker implantation was performed in five patients (15.2%). Bradyarrhythmia recurred without timolol re-exposure in two patients and following re-exposure in one. No deaths attributable to timolol-associated bradyarrhythmia were reported. Published case reports describe clinically significant bradyarrhythmias associated with topical timolol, including events after prolonged treatment. Although improvement following withdrawal was frequently reported, persistent or recurrent conduction abnormalities occurred in some patients. Careful assessment of topical medication exposure and appropriate rhythm monitoring are important in evaluating unexplained bradyarrhythmia. Not applicable.
No takes yet. Share an insight, caveat, or question.
Sadeghi et al. (2026) conducted a systematic review in Bradyarrhythmias temporally associated with topical timolol exposure (n=33). Topical timolol was evaluated on Clinical features, management, and rhythm outcomes of timolol-associated bradyarrhythmias (including sinus bradycardia and atrioventricular block). Topical timolol exposure was associated with sinus bradycardia and AV block; withdrawal yielded favorable outcomes in 72.7%, though 15.2% required permanent pacemakers.
Synapse has enriched 10 related papers. Consider them for comparative context: